UK real-world evidence from EPIC reinforces efficacy and safety profile seen in ELEVATE TN trial
87% of previously untreated CLL patients
receiving Calquence monotherapy were
progression-free at 2 years in both EPIC
and ELEVATE TN1
79% of patients continued
treatment after 2 years in EPIC1
What is EPIC1:
- There were high response rates and acceptable safety profiles observed in acalabrutinib CLL clinical trials. However, UK real world data on acalabrutinib use in the first line (1L) was limited. EPIC was therefore initiated to bride this evidence gap and reiterate the outcomes demonstrated in clinical trials.
- EPIC is a non- interventional observational study of patients with CLL treated with first line acalabrutinib via the early access programme (interim analysis:24 months). In this analysis (data cut off 30/11/23), 1L CLL patients had a minimum of 24 months follow up post-initiation of acalabrutinib via the UK Early Access Programme (EAP). This real-world study will continue with a final analysis at 60 months follow up.
Methodology
Retrospective cohort study (from medical records)
Baseline clinical and demographic characteristics (24 months data cut-off, n=170)1
At 24 months in EPIC, 87% of patients remained progression free and 79% remained on treatment1
View the ELEVATE TN study
View our long-term data in previously untreated patients
Abbreviations:
CIRS-G, Cumulative Illness Rating Scale-Geriatric, COPD, Chronic obstructive pulmonary disease, ECOG PS, Eastern Cooperative Oncology Group Performance Status, GORD, Gastro-oesophageal reflux disease
References:
1. Martinez-Calle, Nicolas, Walewska, Renata, Panees, Shankara et al. OUTCOMES OF EPIC. EHA 2024. Abstract #1256. 2. Sharman JP, et al. Lancet 2020;395:1278–91.
Adverse events should be reported
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to AstraZeneca by visiting contactazmedical.astrazeneca.com or by calling 0800 783 0033.
May 2025 I GB-66027